GSK (GSK) To Acquire Bellus Health (BLU) For $2B

GSK (GSK) reaches agreement to acquire Bellus Health (BLU). George Tsilis joins Alex Coffey and Jenny Horne to discuss this as the deal is worth approximately $2B or $14.75 per share. He talks about how the deal is expected to close in 3Q23 or earlier. BLU is a late-stage biopharma company whose experimental cough medicine "Camlipixant" is expected to launch in 2026. Tune in to find out more about the stock market today.

Next Gen Investing

18 Apr 2023

SHARE

ON AIR
3:00 am
Trading 360
replay
12:00 am
Fast Market
REPLAY
education
1:00 am
Your First Trade
REPLAY
1:30 am
Next Gen Investing
REPLAY
education
2:30 am
Your First Trade
REPLAY
ON AIR
3:00 am
Trading 360
REPLAY
4:00 am
Fast Market
REPLAY
5:00 am
Next Gen Investing
REPLAY
education
6:00 am
Your First Trade
REPLAY
6:30 am
Trading 360
REPLAY
7:30 am
Fast Market
REPLAY
8:30 am
Next Gen Investing
REPLAY
9:30 am
Market Overtime
REPLAY
10:00 am
Trading 360
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Your First Trade
REPLAY
1:30 pm
Trading 360
REPLAY
2:30 pm
Fast Market
REPLAY
3:30 pm
Next Gen Investing
REPLAY
4:30 pm
Market Overtime
REPLAY
5:00 pm
Trading 360
REPLAY
6:00 pm
Fast Market
REPLAY
7:00 pm
Next Gen Investing
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Trading 360
REPLAY
9:30 pm
Fast Market
REPLAY
10:30 pm
Next Gen Investing
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now